Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.65 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | PPARG | P37231 | 12/20 | 0.54 |
| ▸ | PPARA | Q07869 | 12/20 | 0.54 |
| ▸ | PPARD | Q03181 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3523699 | 0.91 | KDR (0.61) | KDRFFAR1MAPTPPARGPPARA | |
| SCHEMBL4394279 | 0.91 | PPARA (0.66) | PPARGPPARAPPARD | |
| SCHEMBL27650832 | 0.84 | KDR (0.54) | KDRFFAR1MAPTPPARGPPARA | |
| SCHEMBL5738898 | 0.84 | PPARA (0.66) | KDRFFAR1MAPTPPARGPPARA | |
| SCHEMBL3528719 | 0.84 | KDR (0.76) | KDRFFAR1MAPTPPARGPPARA | |
| SCHEMBL4391433 | 0.82 | PPARG (0.60) | PPARGPPARAPPARD | |
| SCHEMBL3523858 | 0.81 | KDR (0.51) | KDRFFAR1MAPTPPARGPPARA | |
| SCHEMBL3523856 | 0.81 | KDR (0.51) | KDRFFAR1MAPTPPARGPPARA | |
| SCHEMBL8547074 | 0.81 | KDR (0.69) | KDRFFAR1MAPTPPARGPPARA | |
| SCHEMBL3527831 | 0.81 | KDR (0.69) | KDRFFAR1MAPTPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652061-B2 | N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | disclosed |
| EP-1638963-B1 | N-ACYL NITROGEN HETEROCYCLES AS LIGANDS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS | NOVARTIS AG (CH) | 2009-09-09 | — | — | EP | disclosed |
| US-20060135593-A1 | N-acyl nitrogen heterocyles as ligands of peroxisome proliferator-activated receptors | NOVARTIS AG (CH) | 2006-06-22 | — | — | US | disclosed |
| EP-1638963-A1 | N-ACYL NITROGEN HETEROCYCLES AS LIGANDS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS | Novartis AG (CH) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004103995-A1 | N-ACYL NITROGEN HETEROCYCLES AS LIGANDS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS | NOVARTIS AG (CH) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135593-A1 | N-acyl nitrogen heterocyles as ligands of peroxisome proliferator-activated receptors | PPARG, PPARA, PPARD | KDR 838/4885FFAR1 7/4885MAPT 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.